Nanosponge-based hydrogel preparation of fluconazole for improved topical delivery

Abbas, Nasir; Parveen, Kousar; Hussain, Amjad; Latif, Sajid; Zaman, Shaiq uz; Shah, Pervaiz Akhtar; Ahsan, Muhammad

doi:10.4314/tjpr.v18i2.1

Cited by 24 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, G1 produced the maximum edema inhibition at 5 h (92.91%) in correlation with 69.25% of LX released achieving a controlled anti-inflammatory response [38]. The findings support that nanosponges improved skin permeation and consequently enhanced the anti-inflammatory response [39].…”

Section: Discussionsupporting

confidence: 63%

Lornoxicam-Loaded Nanosponges for Controlled Anti-Inflammatory Effect: In Vitro/in Vivo Assessment

Shawky¹,

Khalifa²,

Eassa³

2020

Int J App Pharm

View full text Add to dashboard Cite

Objective: To design a controlled topical delivery system of lornoxicam (LX) in order to enhance skin permeation and treatment efficacy. Nanosponges were selected as a novel carrier for this purpose. Methods: Nanosponges were formulated via the emulsion solvent evaporation method using ethyl cellulose (polymer) and polyvinyl alcohol (surfactant). Nanosponge dispersions were characterized for colloidal properties, entrapment efficiency and in vitro release study. The nanosponge formulation (LS1) was then incorporated into carboxymethyl cellulose sodium hydrogels and evaluated for pH, viscosity and in vitro drug release. Skin irritation was evaluated, and anti-inflammatory activity was assessed via rat hind paw edema method. Results: Nanosponges were in the nano-sized range and attained a uniform round shape with a spongy structure. LS1exhibited the highest LX release after 6 h, so it was incorporated as hydrogel. Formulated hydrogels showed acceptable physicochemical parameters (pH, drug content and rheological properties). Skin irritation testing proved LX-loaded nanosponge hydrogel formulation (G1) to be non-irritant. In vivo study revealed an enhanced anti-inflammatory activity of G1 for 6 h (p<0.001). Conclusion: The developed nanosponge hydrogel is an efficient nanocarrier for improved and controlled topical delivery of LX.

show abstract

Section: Discussionsupporting

confidence: 63%

Lornoxicam-Loaded Nanosponges for Controlled Anti-Inflammatory Effect: In Vitro/in Vivo Assessment

Shawky¹,

Khalifa²,

Eassa³

2020

Int J App Pharm

View full text Add to dashboard Cite

show abstract

“…Possible reasons could be due to a reduced concentration of polymer in the aqueous phase. In addition, Abbas et al, [21] who formulated fluconazole nanosponges with ethylcellulose and Polyvinyl Alcohol also showed decreasing yield concentrations of nanosponges with increasing polymer concentrations.…”

Section: Discussionmentioning

confidence: 97%

Preparation, physicochemical characterization, and In vivo evaluation of miconazole nitrate nanosponges for the treatment of systemic mycoses

Onwuchekwa¹,

Uronnachi²,

Umeyor³

et al. 2022

GSC Biol. and Pharm. Sci.

View full text Add to dashboard Cite

Miconazole is a Biopharmaceutics Classification System (BCS) class II drug, thus limiting its oral bioavailability. Nanosponges can improve the oral bioavailability of poorly soluble drugs and sustain their release. The work was aimed at formulating miconazole nanosponges to enhance its solubility and consequently, oral bioavailability. Batches of nanosponges incorporating different concentrations (1, 2 and 3 %) of miconazole nitrate were formed using ethyl cellulose (EC), polyvinyl alcohol (PVA), ethanol and Kolliphor® 188. They were characterized using percentage yield, encapsulation efficiency, Differential Scanning Calorimetry (DSC), Xray Diffraction (XRD), particle sizes, polydispersity index (PDI) and Scanning Electron Microscopy (SEM). In vitro antifungal evaluation against Candida albicans was assessed while in vitro release using simulated gastric fluid was done. Furthermore, in vivo release studies in rats were carried out using the bioassay method. The percentage yield of the nanosponges were between 50 to 60 %. Encapsulation efficiencies ranged between 77 and 98 %. Particle sizes ranged between 266.5 and 781.1 nm. Particles were porous and spongy in appearance. Antifungal evaluation of the nanosponges against Candida albicans revealed activity like that of the pure drug. In vitro release studies showed a sustained release pattern for the nanosponges up till 12 hours whereas the unformulated drug peaked at 2 h. In vivo evaluation showed a concentration dependent increase in blood concentration of the drug with NS4 having the highest release. Nanosponges containing miconazole nitrate were successfully formulated and evaluated and are a promising oral delivery system for miconazole nitrate.

show abstract

“…Abbas et al ( 99 ) explored fluconazole-loaded nanosponge-based hydrogel system for improved topical delivery. The prepared nanosponge was evaluated for their entrapment efficiency, particle size, structural properties, and in vitro drug release.…”

Section: Emerging Nanomaterials For the Treatment Of Admentioning

confidence: 99%

Emerging Nanomedicines for the Treatment of Atopic Dermatitis

et al. 2021

View full text Add to dashboard Cite

Globally, the prevalence of Atopic dermatitis (AD) is significantly increasing and affecting around 20% of population including children. Complex interactions amongst abnormality in epidermal barrier function, environment, infectious agents and immunological defects are considered as key factors in the pathogenesis of AD. Although the role of oxidative stress has been studied in some skin diseases, investigation of the same in AD is intermittent. Calcineurin inhibitors and/or topical corticosteroids are currently available; however, it causes atrophy of the skin, burning sensation, and systemic side effects which leads to poor patient compliance. These limitations provoke the strong need to develop an innovative approach in managing AD. Nanomaterials for effective drug delivery to skin conditions such as AD have attracted a lot of attention owing to its ability to encapsulate, protect, and release the cargo at the diseased skin site. However, there are lots of unmet challenges especially in terms of development of non-toxic formulations and clinical translation of established nanomedicines in the form of accessible products. Numerous formulations have emerged as carrier for poorly soluble and permeable drugs, viz., lipidic, polymeric, metal, silica, liposomes, hydrocarbon gels and this field is evolving. This review is intended to provide an insight incidences associated with pathophysiology of AD and challenges with existing treatments of AD. Focus is kept on reviewing current development and emerging nanomedicines for effective treatment of AD. The review also inculcates merits of several nanomedicines in overcoming challenges of existing products and its future implications.

show abstract

Nanosponge-based hydrogel preparation of fluconazole for improved topical delivery

Cited by 24 publications

References 15 publications

Lornoxicam-Loaded Nanosponges for Controlled Anti-Inflammatory Effect: In Vitro/in Vivo Assessment

Lornoxicam-Loaded Nanosponges for Controlled Anti-Inflammatory Effect: In Vitro/in Vivo Assessment

Preparation, physicochemical characterization, and In vivo evaluation of miconazole nitrate nanosponges for the treatment of systemic mycoses

Emerging Nanomedicines for the Treatment of Atopic Dermatitis

Contact Info

Product

Resources

About